Avid­i­ty seeks to 'set the stan­dard' as it heads to FDA with Duchenne drug

Avid­i­ty Bio­sciences shared Mon­day that its RNA drug for peo­ple with cer­tain mu­ta­tions of Duchenne mus­cu­lar dy­s­tro­phy con­tin­ued to show strong re­sults as it com­plet­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER